GlobalData on MSN1 天
Japan’s MHLW approves CSL Behring’s Andembry to stop HAE attacks
CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
PharmaTimes9 天
Andembry treatment approved across Europe
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
Medscape22 天
Angioedema in Heart Failure: Occurrence With ACE Inhibitors and Safety of Angiotensin ...
Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and ...
PMLiVE8 天
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...